55 terminated. 55 Phase 2, 13 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Terminated 55 |
| Phase 1 | 13 | Terminated 13 |
| Phase 3 | 1 | Terminated 1 |
Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 Pociredir - Sickle Cell Disease | Phase 2 | Terminated | Fulcrum Therapeutics | 1 | 2026-03-30 | 2026-10-28 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease ALXN1820 - Sickle Cell Disease (SCD) | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 2 | 2023-02-22 | 2025-01-13 |
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Osivelotor - Sickle Cell Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 47 | 2023-01-05 | 2026-03-19 |
| AB1 in Adult Patients With Sickle Cell Disease (SCD) AB1 - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Nirmish Shah | 16 | 2022-12-05 | 2026-10-15 |
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Voxelotor - Sickle Cell Disease, Sickle Cell Nephropathy | Phase 1 / Phase 2 | Terminated | University of Illinois at Chicago | 12 | 2021-03-16 | 2025-04-03 |
| Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) sapablursen - Beta Thalassemia Intermedia | Phase 2 | Terminated | Ionis Pharmaceuticals, Inc. | 29 | 2020-09-24 | 2025-02-18 |
| A Study of IMR-687 in Subjects With Sickle Cell Disease IMR-687, Placebo - Sickle Cell Disease | Phase 2 | Terminated | Cardurion Pharmaceuticals, Inc. | 115 | 2020-08-13 | 2025-05-15 |
| Imatinib for Pain in Sickle Cell Anemia Imatinib Mesylate - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Indiana University | 7 | 2020-02-26 | 2026-01-29 |
| Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD Voxelotor - Sickle Cell Disease | Phase 2 | Terminated | Pfizer | 6 | 2020-01-09 | 2023-11-21 |
| Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere Hydroxyurea, Hydroxyurea Oral Capsule - Sickle Cell Disease, Thalassemia | Phase 2 | Terminated | St. Jude Children's Research Hospital | 1 | 2019-06-10 | 2022-03-18 |
| Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases Blood and Marrow Transplant - Sickle Cell Disease, Thalassemia | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 5 | 2018-07-02 | 2024-07-12 |
| Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers Topical Sodium Nitrite, Placebo - Sickle Cell Disease | Phase 2 | Terminated | caterina P minniti | 18 | 2018-04-06 | 2025-05-07 |
| Omega-3 Fatty Acids in Sickle Cell Disease SCD-Omegatex™ - Sickle Cell Disease | Phase 1 / Phase 2 | Terminated | Robin E. Miller | 4 | 2018-01-25 | 2020-10-19 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia LJPC-401 - Beta-Thalassemia | Phase 2 | Terminated | La Jolla Pharmaceutical Company | 84 | 2017-11-30 | 2021-07-29 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Rimiducid, rivogenlecleucel - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2017-01-01 | 2023-09-26 |
| Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease Voxelotor - Sickle Cell Disease | Phase 2 | Terminated | Pfizer | 147 | 2016-07-05 | 2025-08-15 |
| Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies CordIn - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Terminated | Gamida Cell ltd | 1 | 2016-04-04 | 2019-06-26 |
Showing 20 of 55. Sign in to see all of them.
Anemia, Sickle Cell (46) · Thalassemia (12) · beta-Thalassemia (8) · Hemoglobin SC Disease (5) · Hypertension, Pulmonary (5) · Anemia, Diamond-Blackfan (4) · Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Vaso-Occlusive Crises (4) · Anemia (3) · Anemia, Aplastic (3) · Lymphoma, Non-Hodgkin (3) · Acute Chest Syndrome (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (55) · Hemic and Lymphatic Diseases (55) · Anemia, Hemolytic, Congenital (54) · Genetic Diseases, Inborn (54) · Hematologic Diseases (54) · Anemia, Hemolytic (53) · Anemia (51) · Cardiovascular Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Respiratory Tract Diseases (7) · Vascular Diseases (7) · Lung Diseases (6) · Thalassemia (6) · Bone Marrow Diseases (5)
Cyclophosphamide (7) · Hydroxyurea (5) · Whole-Body Irradiation (4) · fludarabine phosphate (4) · Busulfan (3) · Sirolimus (3) · Tacrolimus (3) · fludarabine (3) · voxelotor (3) · AP 1903 reagent (2) · Alemtuzumab (2) · Glutamine (2) · Mycophenolic Acid (2) · Pyrrolidonecarboxylic Acid (2) · Rituximab (2)
Baylor College of Medicine (5) · Pfizer (3) · St. Jude Children's Research Hospital (3) · Bellicum Pharmaceuticals (2) · Children's Hospital Los Angeles (2) · University of North Carolina, Chapel Hill (2) · Alexion Pharmaceuticals, Inc. (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Anthera Pharmaceuticals (1) · Baxalta now part of Shire (1) · Boston Children's Hospital (1) · Boston University (1) · Cardurion Pharmaceuticals, Inc. (1) · Carelon Research (1) · Celgene (1)
United States (48) · United Kingdom (8) · Italy (6) · Lebanon (6) · Greece (4) · Turkey (Türkiye) (3) · Australia (2) · Canada (2) · France (2) · Thailand (2) · Egypt (1) · Ghana (1) · Jamaica (1) · Kenya (1) · Morocco (1)
Kenneth I Ataga, MD (2) · Vivien Sheehan, MD (2) · Allistair Abraham, MD (1) · Andrew Gilman, MD (1) · Brigitta Mueller, MD (1) · Caterina Minniti, M.D. (1) · Catherine J. Wu, MD (1) · Christen L Ebens, MD, MPH (1) · Craig D Seaman, MD (1) · Damiano Rondelli, MD (1) · Debra Weiner, MD, PhD (1)
PMID 14550808, PMID 21275961, PMID 21527519, PMID 21900080, PMID 22983573, PMID 23973010, PMID 24677033, PMID 24988120, PMID 25459642, PMID 29296761, PMID 30878319, PMID 31322833, PMID 34014839, PMID 34990411, PMID 35451176, PMID 37254256, PMID 37439373, PMID 37975597, PMID 39428602, PMID 40419809, PMID 41569644, PMID 42224366, PMID 42241700
2019 (2), K23HL127100 (1), P01CA015396 (1), P20GM109021 (1), P30CA006973 (1), R01HL094592 (1), U01HL065232 (1), U01HL065238 (1), U01HL065239 (1), U01HL065244 (1), U01HL065260 (1), U54HL070587 (1)